One VC Firm’s 5 Healthcare Predictions for 2024
MedCity News
DECEMBER 25, 2023
Executives at LRVHealth expect to see a continued focus on generative AI, increased enrollment in Medicare Advantage and more in 2024.
Mon.Dec 25, 2023
129 
Cabometyx by Exelixis for Gastric Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Cabometyx is under clinical development by Exelixis and currently in Phase II for Gastric Cancer.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Why US Healthcare Billing Needs an Overhaul
MedCity News
DECEMBER 25, 2023
Current billing practices do not adequately meet the needs of consumers, providers or payers. While there is no magic wand, reinventing billing processes in the US will require measures that strengthen consumer protection, and continued policy change towards fairer drug pricing and increased price transparency of provider service costs.
Ribociclib succinate by Novartis for Oligodendroglioma: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Oligodendroglioma.
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Who Spearheads Employee Retention Strategies At AdventHealth? Get This — The Employees
MedCity News
DECEMBER 25, 2023
Last month at a conference, AdventHealth CEO Terry Shaw shared some employee retention strategies used at his health system. He stressed the importance of gathering employee feedback and using it to give them the changes they need. This month, MedCity News followed up with AdventHealth to get a better picture of what these strategies look like in practice.
Opaganib by RedHill Biopharma for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Opaganib is under clinical development by RedHill Biopharma and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma).
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
HCW-9218 by HCW Biologics for Ovarian Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
HCW-9218 is under clinical development by HCW Biologics and currently in Phase I for Ovarian Cancer.
The Cover Stories of 2023
PharmExec
DECEMBER 25, 2023
These stories graced the cover of Pharmaceutical Executive this year
ZB-131 by ZielBio for Gallbladder Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
ZB-131 is under clinical development by ZielBio and currently in Phase II for Gallbladder Cancer.
Top 3 Podcast Episodes of the Year
Pharmaceutical Commerce
DECEMBER 25, 2023
This year’s PC Podcast episodes ranged in topic, from DSCSA compliance to pharmacovigilance.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Efineptakin alfa by NeoImmuneTech for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Efineptakin alfa is under clinical development by NeoImmuneTech and currently in Phase II for Solid Tumor.
Top 5 Pharmacy Times Alzheimer Disease Articles of 2023
Pharmacy Times
DECEMBER 25, 2023
From newsworthy moments to groundbreaking research, these were the most-read Alzheimer disease-related articles on Pharmacy Times in 2023.
Disitamab vedotin by RemeGen for Cervical Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Disitamab vedotin is under clinical development by RemeGen and currently in Phase I for Cervical Cancer.
Top 5 Pharmacy Times Pharmacy Technician Articles of 2023
Pharmacy Times
DECEMBER 25, 2023
From newsworthy moments to groundbreaking research, these were the most-read pharmacy technician-related articles on Pharmacy Times in 2023.
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
BDTX-4933 by Black Diamond Therapeutics for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Solid Tumor.
Top 5 Pharmacy Times Biosimilar Articles of 2023
Pharmacy Times
DECEMBER 25, 2023
From newsworthy moments to groundbreaking research, these were the most-read biosimilar-related articles on Pharmacy Times in 2023.
BDTX-4933 by Black Diamond Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.
BDTX-4933 by Black Diamond Therapeutics for Thyroid Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Thyroid Cancer.
BDTX-4933 by Black Diamond Therapeutics for Central Nervous System (CNS) Tumor: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Central Nervous System (CNS) Tumor.
BDTX-4933 by Black Diamond Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Metastatic Colorectal Cancer.
Y-101D by Wuhan YZY Biopharma for Gastric Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Y-101D is under clinical development by Wuhan YZY Biopharma and currently in Phase II for Gastric Cancer.
Y-101D by Wuhan YZY Biopharma for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Y-101D is under clinical development by Wuhan YZY Biopharma and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).
Increase Revenue With Better, Faster Sales Onboarding
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Y-101D by Wuhan YZY Biopharma for Metastatic Colorectal Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Y-101D is under clinical development by Wuhan YZY Biopharma and currently in Phase II for Metastatic Colorectal Cancer.
PRGN-3007 by Precigen for Hematological Tumor: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
PRGN-3007 is under clinical development by Precigen and currently in Phase I for Hematological Tumor.
Dupilumab by Regeneron Pharmaceuticals for Atopic Keratoconjunctivitis: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Atopic Keratoconjunctivitis.
Capivasertib by AstraZeneca for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Capivasertib is under clinical development by AstraZeneca and currently in Phase I for Solid Tumor.
Capivasertib by AstraZeneca for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Capivasertib is under clinical development by AstraZeneca and currently in Phase III for Triple-Negative Breast Cancer (TNBC).
Taladegib by Endeavor BioMedicines for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Taladegib is under clinical development by Endeavor BioMedicines and currently in Phase II for Idiopathic Pulmonary Fibrosis.
Opaganib by RedHill Biopharma for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Opaganib is under clinical development by RedHill Biopharma and currently in Phase I for Solid Tumor.
Ribociclib succinate by Novartis for Prostate Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 25, 2023
Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Prostate Cancer.
Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Let's personalize your content